Steady State Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets
NCT ID: NCT01634373
Last Updated: 2012-07-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Primary objective was to study Steady-state bioequivalence of Torrent's Quetiapine Fumarate Tablets 300 mg.
Study Design:
Randomized, Two-Way, Crossover, multiple Dose, and Open-Label
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Torrent's Quetiapine Fumarate Tablets
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age: 25-65 years
* Patients who are receiving a stable daily dose of quetiapine 300 mg every 12 hourly for atlist one month
* Patient willing to adhere to the protocol requirements
Exclusion Criteria
* Clinically significant abnormal ECG.
* Significant orthostatic hypotension (i.e., a drop in systolic blood pressure of 30 mm Hg or more and/or a drop in diastolic blood pressure of 20 mm Hg or more on standing)
* Concurrent use of antihypertensive medication or any medication that might pre-dispose to orthostatic hypotension.
* History of allergic reactions to quetiapine or other chemically related psychotropic drugs.
* Concurrent primary psychiatric or neurological diagnosis including organic mental disorder, severe tardive dyskinesia, or idiopathic Parkinson's disease.
* Existence of any surgical or medical condition, which in the judgement of the Principal Investigator, might interfere with the absorption, distribution, metabolism or excretion of the drug or likely to compromise the safety of patients.
* Concurrent use of other drugs known to suppress bone marrow function.
* HIV, HCV, HBsAg positive.
* Expected changes in concomitant medications during the period of study.
* A history of epilepsy or risk for seizures
* positive urine drug of abuse test at enrollment.
* A history of alcohol or drug dependence by Diagnostic and statistical manual of Mental disorders IV(DSM-IV) criteria during the 6 month period immediately prior to study entry.
* A total white blood cell count below 4000/ml, or absolute neutrophil count below 2000/ml
* Female patients with pregnancy or Breast feeding or intend to become pregnant during the study and not able to follow contraception methods.
* History of multiple syncopal episodes.
* Administration any study drugs in last 3 months prior to entry in the study.
* History of significant blood loss due to any reason in the past 3 months.
* Any pre-existing bleeding disorder.
25 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Torrent Pharmaceuticals Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asha Hospital
Hyderabad, , India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PK-08-111
Identifier Type: -
Identifier Source: org_study_id